Frontlight ResearchEarly access
Taking peopleNo phase
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
Key facts
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 May 2023
- Expected to end
- 1 Jul 2027
- Type of study
- Observational
- Record updated
- 13 December 2023
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with vulva cancer, tumor > 4 cm, multifocal tumor, or local recurrences in vulva
Who cannot take part
- Previous external irradiation of the vulva or groins
- Known allergy to ICG or iodine
- Patient is in active treatment for other cancer and/or disseminated disease
- Former sentinel node or inguinal lymphadenectomy in the relevant groin
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the study is to evaluate the feasibility of applying the SLN mapping technique in combination with FDG-PET/CT imaging in women with vulva cancer tumour size >4 cm, multifocal tumors and local recurrences.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer ( SENTIVUC II)
- Record updated
- 13 December 2023